{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:13:44Z","timestamp":1786997624608,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.tranon.2025.102539","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:49:48Z","timestamp":1758602988000},"page":"102539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Camizestrant causes reversible pharmacological effects on retinal responses in rats"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6556-6840","authenticated-orcid":false,"given":"Gregory","family":"Hamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Maglennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Purbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-4960","authenticated-orcid":false,"given":"James","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2254-0345","authenticated-orcid":false,"given":"Alexander","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Krakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-7589","authenticated-orcid":false,"given":"James","family":"Ver Hoeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2025.102539_bib0001","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2025.102539_bib0002","doi-asserted-by":"crossref","first-page":"RF0101","DOI":"10.1158\/1538-7445.SABCS23-RF01-01","article-title":"Abstract RF01-01: SERENA-3: a randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer","volume":"84","author":"Robertson","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102539_bib0003","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2025.102539_bib0004","doi-asserted-by":"crossref","first-page":"P3-07-28","DOI":"10.1158\/1538-7445.SABCS22-P3-07-28","article-title":"Abstract P3-07-28: SERENA-1: updated analyses from a phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"83","author":"Turner","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102539_bib0005","doi-asserted-by":"crossref","first-page":"PO3-19-09","DOI":"10.1158\/1538-7445.SABCS23-PO3-19-09","article-title":"Abstract PO3-19-09: SERENA-1: results from a phase 1 study (parts I\/J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+, HER2 advanced breast cancer","volume":"84","author":"Vaklavas","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102539_bib0006","doi-asserted-by":"crossref","first-page":"PS1105","DOI":"10.1158\/1538-7445.SABCS20-PS11-05","article-title":"Abstract PS11-05: updated data from SERENA-1: a phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"81","author":"Baird","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102539_bib0007","series-title":"San Antonio Breast Cancer Symposium","article-title":"Results from SERENA-1 parts K\/L: a phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer","author":"Ruiz-Borrego","year":"2024"},{"key":"10.1016\/j.tranon.2025.102539_bib0008","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.ophtha.2015.06.025","article-title":"Photopsias: a key to diagnosis","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology."},{"key":"10.1016\/j.tranon.2025.102539_bib0009","article-title":"Assessment of photopsia (flashing lights)","volume":"380","author":"Ng","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.tranon.2025.102539_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1242\/jeb.146.1.39","article-title":"The role of sensory adaptation in the retina","volume":"146","author":"Laughlin","year":"1989","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.tranon.2025.102539_bib0011","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00204-021-03197-8","article-title":"Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment","volume":"96","author":"Hamm","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tranon.2025.102539_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10633-014-9473-7","article-title":"ISCEV Standard for full-field clinical electroretinography (2015 update)","volume":"130","author":"McCulloch","year":"2015","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.tranon.2025.102539_bib0013","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.eye.6701573","article-title":"Electrophysiological assessment of optic nerve disease","volume":"18","author":"Holder","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.tranon.2025.102539_bib0014","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/B978-0-444-64032-1.00032-1","article-title":"Chapter 32 - Electroretinograms","volume":"160","author":"Creel","year":"2019"},{"key":"10.1016\/j.tranon.2025.102539_bib0015","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.3390\/jcm11195967","article-title":"The development of electroretinographic oscillatory potentials in healthy young children","volume":"11","author":"Zhang","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tranon.2025.102539_bib0016","article-title":"ON and OFF signaling pathways in the retina and the visual system","volume":"2","author":"Ichinose","year":"2022","journal-title":"Front. Ophthalmol. (Lausanne)"},{"key":"10.1016\/j.tranon.2025.102539_bib0017","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/pharmaceutics12060554","article-title":"Microscale thermophoresis as a screening tool to predict melanin binding of drugs","volume":"12","author":"Hellinen","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.tranon.2025.102539_bib0018","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1021\/acs.molpharmaceut.5b00787","article-title":"Drug distribution to retinal pigment epithelium: studies on melanin binding, cellular kinetics, and single photon emission computed tomography\/computed tomography imaging","volume":"13","author":"Rimpel\u00e4","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tranon.2025.102539_bib0019","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.14412.1","article-title":"Rod and cone interactions in the retina","volume":"7","author":"Fain","year":"2018","journal-title":"F1000Res."},{"key":"10.1016\/j.tranon.2025.102539_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100776","article-title":"Diurnal rodents as pertinent animal models of human retinal physiology and pathology","volume":"74","author":"Verra","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tranon.2025.102539_bib0021","article-title":"The interplay of environmental luminance and genetics in the retinal dystrophy induced by the dominant RPE65 mutation","volume":"119","author":"Wu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.tranon.2025.102539_bib0022","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/jnr.21008","article-title":"Ocular phenotype in a mouse gene knockout model for infantile neuronal ceroid lipofuscinosis","volume":"84","author":"Lei","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.tranon.2025.102539_bib0023","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.taap.2013.09.018","article-title":"A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors","volume":"273","author":"Zhou","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tranon.2025.102539_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135521","article-title":"Crizotinib-induced abnormal signal processing in the retina","volume":"10","author":"Ishii","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.tranon.2025.102539_bib0025","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1167\/iovs.11-7183","article-title":"Mechanism of voriconazole-induced transient visual disturbance: reversible dysfunction of retinal ON-bipolar cells in monkeys","volume":"52","author":"Kinoshita","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:23:06Z","timestamp":1761646986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325002700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"alternative-id":["S1936523325002700"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102539","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Camizestrant causes reversible pharmacological effects on retinal responses in rats","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102539"}}